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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
VeriSol
®P and a change in skin elasticity leading to an improvement in 
skin function pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Gelita AG, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 
via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
was asked to deliver an opinion on the scientific substantiation of a health claim related to VeriSol
®P and a 
change  in  skin  elasticity  leading  to  an  improvement  in  skin  function.  The  Panel  considers  that  the  food, 
VeriSol
®P, which is the subject of the health claim, is sufficiently characterised. The claimed effect proposed by 
the applicant is “maintenance of skin health, as indicated by an increased skin elasticity and a reduction of 
wrinkles volume”. The target population proposed by the applicant is the general adult population. The Panel 
considers that a change in skin elasticity leading to an improvement in skin function is a beneficial physiological 
effect. The applicant presented two human studies, one animal study and one in vitro study as being pertinent to 
the health claim. No conclusions can be drawn from one of the two human studies as it did not assess a function 
of the skin. The second human study assessed a function, i.e. the water barrier function, of the skin, but did not 
show an effect on this function. In the absence of evidence for an effect on skin function in humans, the animal 
and in vitro studies cannot be used for the scientific substantiation of the claim. The Panel concludes that a cause 
and effect relationship has not been established between the consumption of VeriSol
®P and a change in skin 
elasticity leading to an improvement in skin function. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following an application from Gelita AG, submitted pursuant to Article 13(5) of Regulation (EC) No 
1924/2006 via the Competent Authority of Germany for authorisation of a health claim, the EFSA 
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the 
scientific substantiation of a health claim related to VeriSol
®P and a change in skin elasticity leading 
to an improvement in skin function. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food that is the subject of the health claim is VeriSol
®P, which is a collagen hydrolysate derived 
from porcine sources. The Panel considers that VeriSol
®P is sufficiently characterised. 
The claimed effect proposed by the applicant  is “maintenance of skin health, as indicated by an 
increased skin elasticity and a reduction of wrinkles volume”. The target population proposed by the 
applicant is the general adult population. The Panel considers that a change in skin elasticity leading 
to an improvement in skin function is a beneficial physiological effect. 
The applicant presented two human studies, one animal study and one in vitro study as being pertinent 
to the health claim. 
In a randomised, double-blind, placebo-controlled study, 114 women received daily for eight weeks 
2.5 g VeriSol
®P or a placebo. The primary outcome of the study was the volume of eye wrinkles. 
Secondary outcomes were the contents of pro-collagen type I, elastin and fibrillin in suction blister 
biopsies. The Panel notes that this study did not assess a function of the skin, and considers that no 
conclusions can be drawn from this study for the scientific substantiation of the claim. 
In  another  randomised,  double-blind,  placebo-controlled  study, 69 women  received  daily  for 
eight weeks 2.5 g VeriSol
®P, 5 g VeriSol
®P or a placebo. Primary outcomes of the study were skin 
elasticity and skin hydration. Secondary outcomes were transepidermal and transonychial water loss. 
In addition, skin roughness was assessed. The Panel considers that measures of transepidermal water 
loss can be used as scientific evidence for a function, i.e. the water barrier function, of the skin, and 
that measures of the water-holding capacity (hydration) of skin may be used as supportive evidence. 
There  were  no  significant  differences  between  the  groups  for  transepidermal  water  loss  or  skin 
hydration at any time point. The Panel notes that this study did not show an effect on the water barrier 
function of the skin, and that no other function of the skin was measured. 
One animal study in mice and one in vitro study in fibroblasts were provided. The Panel considers 
that in the absence of evidence for an effect of VeriSol
®P on a change in skin elasticity leading to an 
improvement in skin function in humans, the animal and  in vitro studies cannot be used for the 
scientific substantiation of the claim. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of VeriSol
®P and a change in skin elasticity leading to an improvement in skin function. VeriSol
®P and a change in skin elasticity leading to an improvement in skin function 
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BACKGROUND 
Regulation (EC) No 1924/2006
4 harmonises the provisions that relate to nutrition and health claims , 
and establishes rules governing the Community authorisation of health claims made on foods.  As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of  
this Regulation, are authorised in accordance with this Regulation , and are included in the lists of 
authorised claims provided for in Articles 13   and 14 thereof. In particular,  Article 13(5) of this  
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to chi ldren’s  development  and  health)  which  are  based  on  newly  developed 
scientific  evidence,  or  which  include  a  request  for  the  protection  of  proprietary  data,  to  the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted  claims  referred  to  in  Article 13(3)  shall  be  submitted  by  the  applicant  to  the  national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 20/09/2012. 
  The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  based  on  newly 
developed  scientific  evidence.  The  application  included  a  request  for  the  protection  of 
proprietary data. 
  On 29/10/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  On 07/12/2012, EFSA received the missing information as submitted by the applicant. 
  The scientific evaluation procedure started on 20/12/2012. 
  On 28/02/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the 
clock was stopped on 06/03/2013, in compliance with Article 18(3) of Regulation (EC) No 
1924/2006. 
  On  21/03/2013,  EFSA  received  the  requested  information  (which  was  made  available  to 
EFSA in electronic format on 19/03/2013) and the clock was restarted, in compliance with 
Article 18(3) of Regulation (EC) No 1924/2006. 
  During  its  meeting  on  30/05/2013,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to VeriSol
®P and 
a change in skin elasticity leading to an improvement in skin function. 
TERMS OF REFERENCE 
EFSA  is  requested  to  evaluate  the  scientific  data  submitted  by  the  applicant  in  accordance  with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: VeriSol
®P and a change in skin 
elasticity leading to an improvement in skin function. 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. VeriSol
®P and a change in skin elasticity leading to an improvement in skin function 
 
 
EFSA Journal 2013;11(6):3257                        5 
EFSA DISCLAIMER 
The  present  opinion  does  not  constitute,  and  cannot  be  construed  as,  an  authorisation  for  the 
marketing of VeriSol
®P, a positive assessment of its safety, nor a decision on whether VeriSol
®P is, or 
is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. VeriSol
®P and a change in skin elasticity leading to an improvement in skin function 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Gelita AG, Uferstrasse 7, 69412 Eberbach, Germany. 
The application includes a request for the protection of proprietary data for four unpublished studies 
(Oesser, 2010; Schunck, 2011; Westphal, 2012a, 2012b), in accordance with Article 21 of Regulation 
(EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, specific collagen hydrolysates (either from bovine or porcine sources) 
which are produced under the brand names of VeriSol
®B (from bovine sources) and VeriSol
®P (from 
porcine sources). 
Health relationship as claimed by the applicant 
According to the applicant, the collagen hydrolysates (i.e. VeriSol
®B and VeriSol
®P) have an effect 
on the “maintenance of skin health”. This would be indicated by an increase in skin elasticity and a 
reduction of skin wrinkles volume. As the mechanism a contribution to normal collagen and elastin 
synthesis was proposed. 
Wording of the health claim as proposed by the applicant 
The  applicant  has  proposed  the  following  wording  for  the  health  claim:  “characteristic  collagen 
peptide mixture (collagen hydrolysate) having a beneficial physiological effect on the maintenance of 
skin  health,  as  indicated  by  an  increased  skin  elasticity  and  a  reduction  of  wrinkles  volume,  by 
contributing to a normal collagen and elastin synthesis”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed a daily intake of 2.5 g of the product. The target population is the general 
adult population. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
The food that is the subject of the health claim is a collagen hydrolysate produced under the brand 
name of VeriSol
®P. 
The applicant proposed two distinct types of collagen hydrolysate, derived either from bovine (i.e. 
VeriSol
®B)  or  porcine  (i.e.  VeriSol
®P)  sources.  On  the  basis  of  the  studies  provided,  the  Panel 
considers that VeriSol
®P is the subject of the health claim. 
VeriSol
®P is a mixture of collagen peptides produced by enzymatic hydrolysis of type I and type III 
collagen from pig skin gelatine. An overview of the manufacturing process, the typical amino acid 
profile, molecular weight distribution of the collagen peptides (mean 2.0±0.3 kDa), batch-to-batch 
variability and stability data were provided. 
The Panel considers that the food, VeriSol
®P, which is the subject of the health claim, is sufficiently 
characterised. VeriSol
®P and a change in skin elasticity leading to an improvement in skin function 
 
 
EFSA Journal 2013;11(6):3257                        7 
2.  Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant  is “maintenance of skin  health, as indicated by an 
increased skin elasticity and a reduction of wrinkles volume”. The target population proposed by the 
applicant is the general adult population. 
During the validation and assessment of the application, EFSA informed the applicant that a change in 
skin structure contributing to the maintenance (i.e. reduced loss) of skin function might be considered 
a beneficial physiological effect provided that there is evidence that such changes in skin structure 
lead to changes in skin function (EFSA NDA Panel, 2012). The applicant was also informed that 
health claims on the maintenance of normal structure, hydration, elasticity or appearance of the skin 
do  not  necessarily  refer  to  a  particular  physiological  function  of  the  skin  as  required  by 
Regulation (EC)  No  1924/2006;  nor  does  a  decrease  in  wrinkles,  which  may  be  related  to  the 
maintenance or improvement of skin structure/hydration/elasticity (EFSA NDA Panel, 2012). EFSA 
requested the applicant to indicate the function of the skin to which the health claim refers and the 
outcome  measure(s)  which  would  be  appropriate  for  the  assessment  of  the  claim.  In  reply,  the 
applicant indicated that the health claim refers to the mechanical and immune skin barrier function. 
However, the outcome measures proposed by the applicant focused solely on skin elasticity rather 
than immune barrier function. In addition, a number of putative mechanisms were indicated, such as 
an increased expression of extracellular matrix proteins. It was agreed that a change in skin elasticity 
is a beneficial physiological effect provided that it leads to an improvement in skin function. 
The Panel considers that a change in skin elasticity leading to an improvement in skin function is a 
beneficial physiological effect. 
3.  Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed, the Cochrane database, Web of Science and 
Google using the search terms [(“collagen hydrolysate” AND “skin”), (“collagen hydrolysate” AND 
“dietary supplements” AND “skin”), (“collagen peptides” AND (“intake” OR “dietary supplements”) 
AND “skin”)]. Studies were included if they were performed with the specified collagen hydrolysates 
(i.e. VeriSol
®B or VeriSol
®P). No such published studies were identified. 
The applicant presented two unpublished human intervention studies (Westphal, 2012a, 2012b), one 
unpublished animal study (Schunck, 2011) and one unpublished in vitro study (Oesser, 2010) as being 
pertinent to the health claim. All four studies were claimed as proprietary by the applicant. 
In a randomised, double-blind, placebo-controlled study (Westphal, 2012b, unpublished), 114 women 
(mean age 55.6 years, age range 45-65) received daily for eight weeks 2.5 g VeriSol
®P (n = 57) or a 
placebo  (maltodextrin,  n = 57).  Inclusion  criteria  were  female  sex,  45-65 years  of  age,  and  skin 
phototype  I to III  (Fitzpatrick  scale).  The  primary  outcome  of  the  study  was  the  volume  of  eye 
wrinkles. Secondary outcomes were the contents of pro-collagen type I, elastin and fibrillin in suction 
blister biopsies which were taken from a subgroup of participants. 
The Panel notes that this study did not assess a function of the skin, and considers that no conclusions 
can be drawn from this study for the scientific substantiation of the claim. 
In a randomised, double-blind, placebo-controlled study (Westphal, 2012a, unpublished), 69 women 
(mean age 47.8 years, age range 35-55) received daily for eight weeks 2.5 g VeriSol
®P (n = 23), 5 g 
VeriSol
®P  (n = 23)  or  a  placebo  (maltodextrin,  n = 23).  Inclusion  criteria  were  female  sex, 
35-55 years of age, skin phototype I to IV (Fitzpatrick scale) and dry skin on forearms (according to 
self-assessment). Power calculations were based on a previous study (Segger et al., 2008). It was 
estimated  that  20 subjects  per  group  were  required  to  achieve  a  power  of  70 %  for  the  primary 
outcomes of the study which were skin elasticity and skin hydration. Secondary outcomes of the study VeriSol
®P and a change in skin elasticity leading to an improvement in skin function 
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were transepidermal (TEWL) and transonychial (TOWL) water loss. In addition, skin roughness was 
assessed.  The  Panel  considers  that  measures  of  TEWL  can  be  used  as  scientific  evidence  for  a 
function, i.e. the water barrier function, of the skin, and that measures of the water-holding capacity 
(hydration)  of  skin  may  be  used  as  supportive  evidence.  Test  sites  were  the  inner  sides  of  both 
forearms. Measurements were taken at baseline and at weeks four and eight. Seven subjects dropped 
out of the study. Data on 68 subjects were taken into consideration for the analysis (one subject was 
excluded as only base-line data were available). Data were tested for normal distribution using the 
Kolmogorov-Smirnov test. Differences between groups were compared using one-way analysis of 
variance  (ANOVA)  for  normally  distributed  data,  or  the  Kruskal-Wallis  test  for  non-normally 
distributed  data.  There  were  no  significant  differences  between  the  groups  for  TEWL  or  skin 
hydration at any time point. 
The Panel notes that this study did not show an effect on the water barrier function of the skin, and 
that no other function of the skin was measured. 
One  animal  study  (Schunck,  2011,  unpublished)  in  hairless  (i.e.  SKH-1)  mice  was  provided. 
VeriSol
®P or a placebo were administered to 32 male mice for four weeks. Following UV-B light 
irradiation (in order to stimulate skin-ageing), skin hydration, skin elasticity and transepidermal water 
loss were measured. 
One in vitro study (Oesser, 2010, unpublished) investigated gene expression of various extracellular 
matrix molecules (biglycan, decorin, versican and collagen type I), inflammatory cytokines (IL-1β and 
IL-6) and matrix metalloproteinases (MMP-1 and MMP-13) in human primary dermal fibroblasts 
which were exposed to VeriSol
®P. 
The Panel considers that in the absence of evidence for an effect of VeriSol
®P on a change in skin 
elasticity leading to an improvement in skin function in humans, the animal and in vitro studies cannot 
be used for the scientific substantiation of the claim. 
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of VeriSol
®P and a change in skin elasticity leading to an improvement in skin function. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 
  The food, VeriSol
®P, which is the subject of the health claim, is sufficiently characterised. 
  The claimed effect proposed by the applicant is “maintenance of skin health, as indicated by 
an  increased  skin  elasticity  and  a  reduction  of  wrinkles  volume”.  The  target  population 
proposed by the applicant is the general adult population. A change in skin elasticity leading 
to an improvement in skin function is a beneficial physiological effect. 
  A  cause  and  effect  relationship  has  not  been  established  between  the  consumption  of 
VeriSol
®P and a change in skin elasticity leading to an improvement in skin function. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on VeriSol
®P and a change in skin elasticity leading to an improvement in 
skin  function  pursuant  to  Article 13(5)  of  Regulation  (EC)  No  1924/2006  (Claim  serial  No: 
0366_DE). September 2012. Submitted by Gelita AG. VeriSol
®P and a change in skin elasticity leading to an improvement in skin function 
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GLOSSARY/ABBREVIATIONS 
ANOVA    Analysis of variance 
TEWL      Transepidermal water loss  
TOWL     Transonychial water loss 